trial

Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation

NCTId NCT01646840
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 12 (actual)
Sponsored by Biogen
Primary completion 2012-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
12 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2012-07
Primary completion
2012-09
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
PF-04958242 capsulePF-04958242 oral solution

Sponsors

BiogenLead Sponsor

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE1
Primary Completion Date
2012-09
Status
COMPLETED
relationships
The graph out of here
drug
PF-04958242 capsule
drug
PF-04958242 oral solution
drug
lead_sponsor
Biogen
company
indication
Healthy
indication
Schizophrenia
indication